Press Releases

WASHINGTON, DC—Following is a statement by George Vradenburg, chairman of UsAgainstAlzheimer's, on the announcement that Eli Lilly and Company and AstraZeneca's experimental BACE inhibitor drug for Alzheimer's is advancing to Phase 3 clinical trials

WASHINGTON, March 31, 2016—Today’s Alzheimer’s disease drug pipeline, marred by more than a decade of high failure rates and public underinvestment, is offering near-term promise with 17 drugs on pace to launch in the next five years, according to a recent analysis conducted by ResearchersAgainstAlzheimer’s (RA2), an UsAgainstAlzheimer’s (UsA2) network. If only some of those drugs are successful in late-stage trials and cleared by the U.S. Food and Drug Administration (FDA), the potential innovations will be a much-needed stimulus to the goal of stopping America’s most costly disease, one that affects approximately 5.3 million Americans, a number that is expected to rise precipitously during the next few decades.    

WASHINGTON, D.C. – The new Leader’s Guide for Season of Caring (available from Amazon ) is a first-of-its-kind guide to facilitating Alzheimer’s and dementia caregiver support groups. Authored by Dr. Richard L. Morgan and published by UsAgainstAlzheimer’s Clergy Network, the Leader’s Guide provides structure and guidance for a 10-week support group based on the book Seasons of Caring: Meditations for Alzheimer’s and Dementia Caregivers.

WASHINGTON, DC (March 14, 2016) – Trish and George Vradenburg, co-founders of UsAgainstAlzheimer’s, will receive Research!America’s Gordon and Llura Gund Leadership Award for their role and leadership in advancing solutions to the Alzheimer’s crisis.

WASHINGTON, DC (March 7, 2016) – Following is a statement by George Vradenburg, chairman of UsAgainstAlzheimer’s, on the passing of First Lady Nancy Reagan.

Pages

^ Back to Top